Sera from 30 patients, selected only on the basis of having serum theophylline concentrations 18 mg/L, were assayed for total creatine kinase (CK), isoenzyme CK-MB, and cathodaily migrating CK (mCK-2). CK-MB was measured by ionexchange chromatography. mCK-2 was detected by electrophoresis on agarose gel, with fluorometric scanning. The mCK-2 variant was found in 37% of these 30 patients. None of the patients in the mCK-2 group had CK-MB values exceedingthe cutoffvalue associatedwith myocardialinfarction, so extensivecardiac ischemiawas consideredunlikely. A review of the patients'records supportedthis conclusion, and no particular association with any specific disease was found among the mCK-2 group. Investigations with use of goat anti-CK-MM and anti-theophylline indicated that neither CK-MM nor theophylline were present in the mCK-2. Results of specific radioimmunoassay for CK-B subunit were negative. The mobility of the mCK-2 peak was unresponsive to 2-mercaptoethanol, suggesting that CK of mitochondrial origin was not present. These results provide insight into the clinical relevance of mCK-2 and some information concerning its composition.
of theophylline-treated patients, an observation that suggests that results of mCK-2 assay must be interpreted with caution.
Materials and Methods
Sera were chosen without conscious bias from samples that were being routinely assayed for theophylline. The only criterion for acceptance was a serum theophylline concentration of 18 mgfL or greater, as measured with a conventional enzyme-coupled immunoassay system (EMrr'1; Syva Co., Palo Alto, CA 94303). The suggested upper limit of therapeutic effectiveness for theophylline in our institution is 18 mg/L. Total CK activity (reference upper limit; 120 UI L) was measured by ultraviolet spectrometry by continuousflow (SMACR; Technicon Instruments Corp., Tarrytown,
NY

10591). CK-MB was quantified by column chromatography, according to the technique of Mercer (13) as modified by Klein et a!. (14)
and by Delahunty and Balkcom (15) . In addition, CK isoenzymes (in 3-/LL aliquots of serum) were also separated by electrophoresis on agarose gel, and their positions were identified by use of CK reagents supplied by Corning Medical and Scientific, Medfield, MA 02052. Control serum containing the three major human CK isoenzymes was from Roche Diagnostics, Nutley, NJ 07110. A serum was designated as containing mCK-2 if a peak or shoulder was present at least 5 mm from the apex of the CK-MM peak. To ensure that the fluorescent bands obtained represented actual CK activity, I repeated the electrophoresis, using sera from four patients, and incubated the membranes with CK reagent lacking creatine phosphate. In each case the mCK-2 band was found to contain genuine CK activity. The anti-theophylline and anti-CK-MM immunoglobulin used in this study were supplied with the EMF and Isommune'1 (Roche Diagnostics) kits, respectively. The antitheophylline antibody reagent was concentrated threefold and dialyzed overnight against 2 L of 9 g/L NaC1. After electrophoresis, the dried gel membranes were scanned fluorometncally with a densitometer (Model CDS-200; Beckman Instruments Inc., Fullerton, CA 92634). The CK-B subunit was determined by RIA with a kit supplied by Mallinckrodt Inc., St. Louis, MO 63134. The patients' hospital records were examined for the clinical diagnosis; in particular, I sought evidence for neoplasms and cardiac ischemia. Figure 1 shows the fluorescent scan obtained after electrophoresis of various sera. As can be seen in Figure la On the other hand, with sera from two other patients who were not part of our theophylline study (J.M. and M.S.), mercaptoethanol in this concentration caused a significant anodal shift in the CK-MB and mCK-1 peaks relative to their usual positions ( Figure 2 ). As shown in Figure 3 , when anti-CK-MM was premixed with the CK reagents (112 by volume), the peak due to CK-MM in control or patients' serum was much smaller, but the peaks due to mCK-2 (patient B.M.) or CK-BB (control serum) were not. Similarly, when the same experiment was repeated with anti-theophylline instead of anti-CK-MM, the amplitudes of the CK-MM and mCK-2 peaks from patient O.B. were not affected ( Figure   3 , e and f). I repeated these experiments with antiserum, using samples from two other mCK-2 patients (K.G. and B.G.), with the same result When another specimen was drawn from patient KG. one week after the serum theophylline In Table 1 I compare laboratory and diagnostic data on the 30 patients with serum theophylline concentrations of 18 mg/L or greater. Because the serum samples were chosen without conscious bias from among the specimens received by the toxicology laboratory, they represented various intervals of therapy, a variable not assessed for this study. Eleven patients in the group had discernible mCK-2 in their serum, a prevalence of 37%. Serafrom three other theophylline-treated patients were analyzed, but were not included in either group because only a very weakly fluorescent mCK-2 band was seen. The mean activities of total CK in serum were 83 U/L for the mCK-2 group and 220 U/L for the non-mCK-2 group (p = 0.111); their CK-MB activities were 39 and 9.2 U/L, respectively (p = 0.082). There was no significant difference in the mean ages of the two patient groups (53 and 66 years, respectively) or in the concentrations of theophylline in the serum (23 and 25 mg/L, respectively). Table 1 also shows that two patients in the mCK-2 group and one patient in the non-mCK-2 group had carcinomas and that most of the patients in both groups suffered from asthma and related conditions. Patients B.S. and A.F. had seizures, suggesting that the theophylline concentration reached toxic levels in these cases. In the case of patient 
Results
J.W. it is not clear whether high theophylline concentration
(70 mg/L) was a contributory factor in his death.
Discussion
The high prevalence (37%) of mCK-2 that I found among patients with relatively high concentrations of theophylline in their serum contrasts with the prevalence of 2.6% among patients in intensive care (17) , 0.8% among adult patients only (18) , and 0.15% (11) , 0.3% (18) , and 1.7% (6) among unselected patients. It indicates a clear association between theophylline administration and the presence of mCK-2. Preincubation of serum containing only CK-MM with theophylline in a final concentration of 25 mgIL at 37 #{176}C for 1 h did not result in the appearance of an mCK-2 peak, making it likely that this association is strictly an in vivo phenomenon (results not illustrated). In this regard, it would be interesting to repeat this experiment using the major theephylline metabolites, 1,3-dimethyluric acid and 1-methylunc acid.
Goat anti-serum to CK-MM did not inhibit the mCK-2 activity. Evidently, no CK-MM is present in this atypical band. This result accords with that of Urdal and Landaas (18), who concluded that mCK-2 contained CK-BB--a conclusion that appears to be unwarranted, in that two patients' sera containing mCK-2 in our study had undetectable amounts of immunoreactive CK-B when assayed by an RIA specific for the B subunit of CK, although two other patients with mCK-1 (M.S. and L.D.) did have substantial amounts of CK-B in their blood. Anti-theophylline did not inhibit the appearance of either the mCK-2 or CK-MM peaks, which indicates that the drug does not bind to either form of the enzyme. Also, the electrophoretic behavior of the mCK-2 in the presence of mercaptoethanol suggests that it is not derived from cardiac mitochondria as proposed by James and Harrison (17) , who found that the mobility of the initochondrial enzyme clearly shifts towards the anode when preincubated with this reducing reagent. The similar shift found in the mobility of mCK-1 and CK-MB (but not mCK-2) as reported here warrants further study. Although I saw considerable variation in serum CK activity among both groups of patients, I did not expect to find that the mean total CK and CK-MB activities in the mCK-2 group were less than half that in the non-mCK-2 group. Furthermore, the fact that none of the patients in the mCK-2 group had serum activities of CK-MB above the cutoff for myocardial infarction (15) suggests that this atypical mCK-2 was not of cardiac origin. The patient's data support this conclusion, no association with cardiac ischemia being found in this group. In contrast to mCK-1, which is most commonly seen in serum from older patients (6, 7), there was no significant difference in age distribution between the two groups studied.
Several research groups have presented evidence of a strong association between the presence of neoplasms and mCK-2 (5, 9-11). Indeed, two of the patients in our mCK-2 group had carcinomas. However, the data also indicate that the presence of mCK-2 in the serum is not necessarily associated with a terminal illness, either neoplastic or cardiac disease, because most of our patients were receiving theophylline for the treatment of chronic and acute asthmatic conditions. Because patients suffering from cardiac conditions are often given theophylline to improve associated respiratory congestion, it is tempting to speculate that the presence of mCK-2 in the sera of such patients, as reported by other workers (6, 10, 12), was in fact an in vivo effect of this drug. I am continuing efforts to elucidate further the nature of the mCK-2 enzyme in theophyllinetreated patients.
